Drug Trial Radar · NCT07939152
Prospective Randomized Trial Protocol for Duration of Post-Operative Tazocin Treatment After Whipple Operation
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Mar 9, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Tel-Aviv Sourasky Medical CenterGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pancreaticoduodenectomy (Whipple procedure) is associated with substantial postoperative morbidity, mainly infectious complications and postoperative pancreatic fistula. Perioperative antibiotic prophylaxis is routine, but the optimal strategy for postoperative antibiotic administration is unclear, and practice varies between surgeons. The objective of this study is to determine whether the duration of postoperative piperacillin-tazobactam (24 hours versus 5 days) affects postoperative infectious outcomes in patients undergoing pancreaticoduodenectomy. This is a single-center, prospective, randomized clinical trial in adults undergoing open or minimally invasive (robotic) pancreaticoduodenectomy. All consented patients receive perioperative piperacillin-tazobactam according to institutional practice. After the operation is completed, patients who underwent pancreaticoduodenectomy and remain eligible are randomized by a computerized system, stratified by presence of a preoperative biliary stent and by surgical approach, to postoperative antibiotic treatment for 24 hours or 5 days. The primary endpoint is the rate of postoperative infectious complications, comprising superficial wound infection, deep (fascial) surgical site infection, and intra-abdominal infection, defined according to CDC criteria, \[within 30 days after surgery\]. Participation does not change surgical technique, length of hospitalization, or routine follow-up. As an exploratory component, intraoperative bile cultures are collected to describe biliary microbial profiles and antibiotic resistance patterns. The study aims to provide high-quality evidence to guide postoperative antibiotic management and support more rational use of broad-spectrum antibiotics in pancreatic surgery.
Conditions
- Post Operative Surgical Site Infection
- Pancreatic Leak
Interventions
piperacillin-tazobactamDrug
Intravenous piperacillin-tazobactam. All participants receive 4.5 g (dose and interval adjusted for renal function) within 60 minutes before incision, with additional intraoperative doses every 2-4 hours until the end of surgery. After surgery, participants receive 4.5 g three times daily (or a reduced dose according to renal function) for either 5 days or 24 hours, according to randomization.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of surgical site infection (SSI) after pancreaticoduodenectomyTime frame: Within 30 days after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Hepatobiliary Surgery, Tel Aviv Sourasky Medical Center Tel Aviv, Israel
Tel Aviv, Tel Aviv, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.